[
 {
  "trial": "T013",
  "source": "registry",
  "arms": {
   "Ketamine Group": {
    "randomized": "6",
    "analysed": "0"
   },
   "No ketamine group": {
    "randomized": "6",
    "analysed": "0"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Adverse events",
    "values": {
     "Ketamine Group": {
      "any_ae": "0"
     },
     "No ketamine group": {
      "any_ae": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT02422303",
   "date": null
  },
  "note": "Registry posted results only. The primary outcome (Goldberg Depression Screening Test, one week) lists 0 analysed in each arm and no values, so there are no depression entries; analysed '0' is that printed count. Participant flow: STARTED 6/6, COMPLETED 5/5. any_ae '0' stands for the registry's printed 'serious 0/6, other 0/6' in each arm. Registry label 'No Ketamine Group' is the design's 'No ketamine group'. No enrollment dates given."
 },
 {
  "trial": "T014",
  "source": "abstract",
  "arms": {
   "Group K": {
    "randomized": null,
    "analysed": null
   },
   "Group C": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 1,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group K": {
      "mean": "2.4",
      "sd": "0.5",
      "n": null
     },
     "Group C": {
      "mean": "2.6",
      "sd": "0.5",
      "n": null
     }
    }
   },
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 2,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group K": {
      "mean": "2.0",
      "sd": "0.4",
      "n": null
     },
     "Group C": {
      "mean": "2.3",
      "sd": "0.5",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2015-06",
   "end": "2016-05"
  },
  "registration": null,
  "note": "Abstract only. 66 randomized in total; per-arm numbers not given (by 6 months 2 lost in group C, 1 in group K). HADS reported only by P values (no difference preoperatively and at 5 d; group K lower at 3 and 6 months), so no depression entries. VAS printed as (x±y) without saying SD; recorded as mean_sd. The abstract's VAS sequence is PACU, 4 h, 24 h, 2 d, 3 d, 4 d, 5 d: day 1 is the 24 h value and day 2 the 2 d value. Analgesic consumption only as P<0.05. PMPS incidence at 3 and 6 months (25% and 22% vs 52% and 45%) is outside the day 1/2 pain window. Enrollment dates are from the abstract's Methods."
 },
 {
  "trial": "T025",
  "source": "abstract",
  "arms": {
   "Ketamine": {
    "randomized": null,
    "analysed": "41"
   },
   "Normal saline": {
    "randomized": null,
    "analysed": "43"
   }
  },
  "depression": [
   {
    "measure": "Montgomery-Asberg Depression Rating Scale",
    "day": 3,
    "form": "count",
    "location": "abstract",
    "definition": "treatment response: >=50% reduction from the baseline MADRS score (events are responders)",
    "values": {
     "Ketamine": {
      "events": "17",
      "n": "41"
     },
     "Normal saline": {
      "events": "7",
      "n": "43"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. 84 enrolled; per-arm randomized numbers not printed; 41 and 43 are the denominators of both response and remission. The day-3 count records responders (improved patients), not patients with depression (RR 2.51, 95% CI 1.18-5.50). Not entered because its day is not given: MADRS remission at discharge, 12/41 (29.3%) ketamine vs 3/43 (7.0%) saline, RR 4.20 (95% CI 1.28-13.80); the remission threshold is not stated. No MADRS scores printed. Adverse events only described in words (none substantially higher with ketamine)."
 },
 {
  "trial": "T029",
  "source": "fulltext",
  "arms": {
   "S-ketamine group": {
    "randomized": "61",
    "analysed": "60"
   },
   "Placebo group": {
    "randomized": "63",
    "analysed": "60"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (also Table 1)",
    "values": {
     "S-ketamine group": {
      "mean": "19.0",
      "sd": "3.59",
      "n": "60"
     },
     "Placebo group": {
      "mean": "19.5",
      "sd": "3.73",
      "n": "60"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "10.7",
      "sd": "4.80",
      "n": null
     },
     "Placebo group": {
      "mean": "15.5",
      "sd": "5.04",
      "n": null
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "-8.8",
      "sd": "3.27",
      "n": null
     },
     "Placebo group": {
      "mean": "-3.5",
      "sd": "2.17",
      "n": null
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (also Table 1)",
    "values": {
     "S-ketamine group": {
      "mean": "15.6",
      "sd": "2.65",
      "n": "60"
     },
     "Placebo group": {
      "mean": "15.2",
      "sd": "2.45",
      "n": "60"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "8.9",
      "sd": "3.45",
      "n": null
     },
     "Placebo group": {
      "mean": "13.0",
      "sd": "3.44",
      "n": null
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "-6.7",
      "sd": "2.53",
      "n": null
     },
     "Placebo group": {
      "mean": "-2.2",
      "sd": "1.49",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "opioid use during hospital stay (morphine equivalents)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (text: within 2 days after surgery)",
    "values": {
     "S-ketamine group": {
      "mean": "16.4",
      "sd": "5.9",
      "n": "60"
     },
     "Placebo group": {
      "mean": "23.9",
      "sd": "8.4",
      "n": "60"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3",
    "values": {
     "S-ketamine group": {
      "dizziness": "5"
     },
     "Placebo group": {
      "dizziness": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09-01",
   "end": "2022-03-01"
  },
  "registration": {
   "number": "NCT05506787",
   "date": null
  },
  "note": "61 S-ketamine and 63 placebo randomized; 1 and 3 lost; 60 per arm analysed. Tables list Placebo before S-Ketamine. Baselines in Table 1 (mean ± SD) and Table 2 (mean (SD)) agree. HAMD-17 and PHQ-9 on days 1, 3 and 30 and NRS on days 1 and 2 are only in Figure 2, without printed values. Table 2 also gives day-7 treatment differences (HAMD-17 -5.3, SE 0.50, 95% CI -6.3 to -4.3; PHQ-9 -4.5, SE 0.38, 95% CI -5.2 to -3.7), not recorded since arm values are given. Source prints minus signs as U+2212. Opioid: Methods say use throughout the hospital stay, but the Results text gives the Table 3 values as consumption within 2 days after surgery, so day 2. Table 3 'Dysphoria' 4 (6.7) S-ketamine vs 1 (1.7%) placebo (text calls it irritability) is not coded to a category."
 },
 {
  "trial": "T035",
  "source": "library",
  "arms": {
   "S-ketamine group": {
    "randomized": "40",
    "analysed": "39"
   },
   "Saline group": {
    "randomized": "40",
    "analysed": "38"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "S-ketamine group": {
      "median": "5",
      "q1": "4",
      "q3": "7",
      "n": "39"
     },
     "Saline group": {
      "median": "6",
      "q1": "4",
      "q3": "7.8",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "S-ketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "6.0",
      "n": "39"
     },
     "Saline group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "8.0",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "count",
    "location": "Table 4",
    "definition": "HADS-D score >7",
    "values": {
     "S-ketamine group": {
      "events": "6",
      "n": "39"
     },
     "Saline group": {
      "events": "5",
      "n": "38"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "2.5",
      "sd": "0.51",
      "n": null
     },
     "Saline group": {
      "mean": "2.8",
      "sd": "0.66",
      "n": null
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "2.1",
      "sd": "0.61",
      "n": null
     },
     "Saline group": {
      "mean": "2.6",
      "sd": "0.76",
      "n": null
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "3.6",
      "sd": "0.59",
      "n": null
     },
     "Saline group": {
      "mean": "4.3",
      "sd": "0.64",
      "n": null
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes text",
    "values": {
     "S-ketamine group": {
      "mean": "3.3",
      "sd": "0.57",
      "n": null
     },
     "Saline group": {
      "mean": "3.7",
      "sd": "0.69",
      "n": null
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "count",
    "location": "Table 4",
    "definition": "patients given rescue analgesia within the 48 h study period",
    "values": {
     "S-ketamine group": {
      "events": "9",
      "n": "39"
     },
     "Saline group": {
      "events": "17",
      "n": "38"
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "S-ketamine group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "75.0",
      "n": "39"
     },
     "Saline group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "100.0",
      "n": "38"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Results, Secondary Outcomes text; Discussion",
    "values": {
     "S-ketamine group": {
      "visual": "1",
      "hallucination": "0",
      "dissociation": "0",
      "dizziness": "0",
      "nightmare": "0"
     },
     "Saline group": {
      "visual": "0",
      "hallucination": "0",
      "dissociation": "0",
      "dizziness": "0",
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05",
   "end": "2021-12"
  },
  "registration": {
   "number": "ChiCTR2100046552",
   "date": null
  },
  "note": "PDF text: '§' stands for '±'. Randomized per arm from the sample size paragraph ('the authors enrolled 40 patients per group'); 80 enrolled, 3 excluded, 77 analysed (39 and 38, Tables 1-4). HADS-D day 2 from Table 4; the text prints the same values without decimals (4 [3-6] v 6 [5-8]). NRS at 24 and 48 h are from the text (S-ketamine first); the abstract gives p = 0.006 at 48 h rest where the text gives 0.005. Rescue analgesia: the count is patients given rescue analgesia, the median_iqr is bucinnazine mg within 48 h (text 0 [0-75] v 0 [0-100]). Adverse events: Results say only 1 patient had an S-ketamine-related adverse event (prespecified: illusions, dissociation, diplopia, nystagmus, dizziness, dreams, urinary retention) and the Discussion says it was 1 diplopia in the S-ketamine group; the zeros are stated in words, not printed. Illusions coded as hallucination, dreams as nightmare."
 },
 {
  "trial": "T036",
  "source": "fulltext",
  "arms": {
   "K1 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "K2 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "K3 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "C group": {
    "randomized": "26",
    "analysed": "26"
   }
  },
  "depression": [
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "K1 group": {
      "mean": "7.4",
      "sd": "3.2",
      "n": "26"
     },
     "K2 group": {
      "mean": "7.4",
      "sd": "4.9",
      "n": "26"
     },
     "K3 group": {
      "mean": "7.4",
      "sd": "3.7",
      "n": "26"
     },
     "C group": {
      "mean": "7.4",
      "sd": "4.0",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "K1 group": {
      "mean": "10.2",
      "sd": "4.3",
      "n": "26"
     },
     "K2 group": {
      "mean": "10.2",
      "sd": "5.0",
      "n": "26"
     },
     "K3 group": {
      "mean": "6.5",
      "sd": "4.1",
      "n": "26"
     },
     "C group": {
      "mean": "11.2",
      "sd": "3.7",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "K1 group": {
      "mean": "10.3",
      "sd": "4.8",
      "n": "26"
     },
     "K2 group": {
      "mean": "10.3",
      "sd": "5.2",
      "n": "26"
     },
     "K3 group": {
      "mean": "5.7",
      "sd": "3.9",
      "n": "26"
     },
     "C group": {
      "mean": "10.8",
      "sd": "3.7",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "K1 group": {
      "mean": "9.8",
      "sd": "4.7",
      "n": "26"
     },
     "K2 group": {
      "mean": "9.9",
      "sd": "5.4",
      "n": "26"
     },
     "K3 group": {
      "mean": "4.5",
      "sd": "3.3",
      "n": "26"
     },
     "C group": {
      "mean": "10.1",
      "sd": "3.8",
      "n": "26"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "emergence",
    "location": "Table 6 (30 min after extubation); Results, Safety Analysis text",
    "values": {
     "K1 group": {
      "agitation": "3",
      "dizziness": "0",
      "visual": "0"
     },
     "K2 group": {
      "agitation": "3",
      "dizziness": "0",
      "visual": "0"
     },
     "K3 group": {
      "agitation": "2",
      "dizziness": "0",
      "visual": "0"
     },
     "C group": {
      "agitation": "1",
      "dizziness": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2015-01",
   "end": "2017-10"
  },
  "registration": null,
  "note": "Tables call the control arm 'Control group' (= C group). 26 per group randomized and analysed. HAD-D 'Time_0 h' is the preoperative baseline (text: 'before operation'; all 7.4), so day -1; 24, 48 and 72 h are days 1, 2, 3. VAS only 30 min after extubation, so no pain entries. Adverse events at 30 min after extubation (Table 6): the 'Dysphoria' row is coded as agitation because the text calls it emergence agitation. Not coded: delirium at 30 min (K1 2, K2 1, K3 1, C 0; all 0 at the second assessment) and dysphoria at leaving the operating/recovery room (2, 2, 1, 1). Dizziness and visual zeros are from the text ('No dizziness, nausea, vomiting, diplopia, or other adverse reactions were found 30 min after extubation'), not printed. Enrollment dates from Methods. No registration given."
 },
 {
  "trial": "T045",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "75",
    "analysed": "62"
   },
   "Control group (saline; PCIA without esketamine)": {
    "randomized": "75",
    "analysed": "61"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 2 (Before surgery)",
    "values": {
     "Esketamine group": {
      "median": "7.0",
      "q1": "4.0",
      "q3": "10.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "9.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": -1,
    "form": "count",
    "location": "Table 2 (Before surgery)",
    "definition": "EPDS score ≥ 13",
    "values": {
     "Esketamine group": {
      "events": "5",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2 (3 days postpartum)",
    "values": {
     "Esketamine group": {
      "median": "6.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "9.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "count",
    "location": "Table 2 (3 days postpartum)",
    "definition": "EPDS score ≥ 13",
    "values": {
     "Esketamine group": {
      "events": "4",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "median_iqr",
    "location": "Table 2 (42 days postpartum)",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.5",
      "q1": "3.0",
      "q3": "8.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "location": "Table 2 (42 days postpartum)",
    "definition": "EPDS score ≥ 13",
    "values": {
     "Esketamine group": {
      "events": "5",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "8",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "median_iqr",
    "location": "Table 2 (3 months postpartum)",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "1.5",
      "q3": "8.0",
      "n": "60"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "9.0",
      "n": "59"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "count",
    "location": "Table 2 (3 months postpartum)",
    "definition": "EPDS score ≥ 13",
    "values": {
     "Esketamine group": {
      "events": "6",
      "n": "60"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "7",
      "n": "59"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 180,
    "form": "median_iqr",
    "location": "Table 2 (6 months postpartum)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "0.0",
      "q3": "8.0",
      "n": "57"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.5",
      "q1": "2.0",
      "q3": "9.0",
      "n": "57"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 180,
    "form": "count",
    "location": "Table 2 (6 months postpartum)",
    "definition": "EPDS score ≥ 13",
    "values": {
     "Esketamine group": {
      "events": "4",
      "n": "57"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "57"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "median": "1.0",
      "q1": "0.0",
      "q3": "1.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "1.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS during coughing",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "4.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS during coughing",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "cumulative sufentanil consumption 0-48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Results 3.3, text (first 24 h)",
    "values": {
     "Esketamine group": {
      "mean": "37.8",
      "sd": "7.4",
      "n": null
     },
     "Control group (saline; PCIA without esketamine)": {
      "mean": "47.3",
      "sd": "8.3",
      "n": null
     }
    }
   },
   {
    "measure": "cumulative sufentanil consumption 0-48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Results 3.3, text (48 h)",
    "values": {
     "Esketamine group": {
      "mean": "74.5",
      "sd": "12.3",
      "n": null
     },
     "Control group (saline; PCIA without esketamine)": {
      "mean": "86.4",
      "sd": "13.5",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "hallucination": "3",
      "nightmare": "1",
      "dizziness": "10"
     },
     "Control group (saline; PCIA without esketamine)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "2"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "hallucination": "2",
      "nightmare": "1",
      "dizziness": "6"
     },
     "Control group (saline; PCIA without esketamine)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05",
   "end": "2021-12"
  },
  "registration": {
   "number": "ChiCTR2100046049",
   "date": null
  },
  "note": "Randomized per arm from the sample size paragraph ('we enrolled 75 patients in each group'); 150 randomized; 13 esketamine and 14 control excluded (consent withdrawal 6/8, lost 7/6); 62 and 61 analysed. EPDS from Table 2: median (IQR) and PPD risk (EPDS ≥ 13; Methods say > 12) before surgery and at 3 d, 42 d, 3 months (n = 60, 59) and 6 months (n = 57, 57); n at the other times is the table header N. EPDS AUC 130.2 ± 115.9 vs 152.2 ± 126.6 not recorded. Sufentanil 0-24 h and 0-48 h from the text; 0-12, 12-24 and 24-48 h only in Figure 2. Adverse events from Table 4; the text says intraoperative dizziness was 'significantly lower in the esketamine group' though its own figures (16.1% vs 3.3%) and the table show it higher; table values recorded. Enrollment dates from Methods."
 },
 {
  "trial": "T071",
  "source": "fulltext",
  "arms": {
   "Ketamine": {
    "randomized": "16",
    "analysed": null
   },
   "Normal saline placebo": {
    "randomized": "16",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "MADRS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (and Results text)",
    "values": {
     "Ketamine": {
      "median": "14.5",
      "q1": "9",
      "q3": "21",
      "n": "16"
     },
     "Normal saline placebo": {
      "median": "12.5",
      "q1": "6",
      "q3": "23.5",
      "n": "16"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 4,
    "form": "median_iqr",
    "location": "Results, Collection of clinical outcomes text",
    "values": {
     "Ketamine": {
      "median": "4",
      "q1": "2",
      "q3": "16",
      "n": null
     },
     "Normal saline placebo": {
      "median": "6",
      "q1": "3.5",
      "q3": "12",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "total opioid dose (oral morphine equivalents) to 07:00 post-infusion day 2",
    "day": 2,
    "form": "median_iqr",
    "location": "Results, last paragraph",
    "values": {
     "Ketamine": {
      "median": "78.2",
      "q1": "52.5",
      "q3": "219",
      "n": null
     },
     "Normal saline placebo": {
      "median": "118",
      "q1": "32.2",
      "q3": "179.5",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 2 (during the study infusion)",
    "values": {
     "Ketamine": {
      "dizziness": "5",
      "visual": "2",
      "agitation": "0"
     },
     "Normal saline placebo": {
      "dizziness": "2",
      "visual": "1",
      "agitation": "1"
     }
    }
   }
  ],
  "blinding_check": {
   "who": "participants",
   "when": "the day after the infusion",
   "location": "Results, Study medication administration",
   "values": {
    "Ketamine": {
     "correct": "7",
     "n": "16"
    },
    "Normal saline placebo": {
     "correct": "7",
     "n": "16"
    }
   }
  },
  "enrollment": {
   "start": "2022-05-05",
   "end": "2023-02-21"
  },
  "registration": {
   "number": "NCT05233566",
   "date": "2022-02-10"
  },
  "note": "Feasibility trial; 16 per arm (Table 1); no per-arm analysed n (MADRS done at 170 of 192 planned time points). Study drug started after extubation; days are post-infusion days. The infusion was on the day of surgery for 28/32 (delayed to POD 1 for 3 control and POD 2 for 1 ketamine participant). MADRS on days 1, 2, 7 and 14 only in Figure 4 (box plots). Adjusted difference in median change to day 4: -1.00 (95% CI -3.23 to 1.73), not recorded since arm medians are given. Preoperative MADRS categories (Table 1): 0-6 3 vs 5; 7-19 6 vs 5; 20-34 6 vs 5; 35-60 1 vs 1. Pain scores only in supplementary figures. Opioid window runs from the infusion start to 07:00 on post-infusion day 2; coded day 2 as the design does. Adverse events from Table 2, midway through the post-extubation infusion (PACU), coded postoperative; 3 control participants refused or could not be interviewed, so control side-effect percentages use 13. Agitation = RASS +1 (Restless). Not coded because they would need summing: BPRS hallucinatory behaviour (ketamine 16 no symptoms; control 11 no symptoms, 1 score 2, 1 score 3) and CADSS-6 (ketamine 9 no symptoms, 3 score 1, 1 score 2, 1 score 3, 2 score 4; control 11 no symptoms, 1 score 4, 1 score 6). Also thinking feels foggy 9 vs 4, concentration/memory trouble 7 vs 3. Enrollment = participants included 5 May 2022 to 21 February 2023 (recruitment 11 April 2022 to 17 February 2023). One control participant died on postoperative day 13."
 },
 {
  "trial": "T076",
  "source": "fulltext",
  "arms": {
   "Sufentanil group (S1)": {
    "randomized": "45",
    "analysed": "44"
   },
   "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
    "randomized": "45",
    "analysed": "42"
   },
   "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
    "randomized": "45",
    "analysed": "41"
   }
  },
  "depression": [
   {
    "measure": "HAM-D",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "14.02",
      "sd": "1.95",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "14.31",
      "sd": "2.29",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "14.51",
      "sd": "2.23",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "14.18",
      "sd": "1.97",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "13.38",
      "sd": "1.67",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "12.41",
      "sd": "1.73",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "12.30",
      "sd": "1.75",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "11.55",
      "sd": "1.73",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "10.73",
      "sd": "1.41",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 5,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "10.57",
      "sd": "1.66",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "9.64",
      "sd": "1.50",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "9.49",
      "sd": "1.27",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "8.68",
      "sd": "1.14",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "8.52",
      "sd": "1.29",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "8.49",
      "sd": "0.95",
      "n": "41"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS (1, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "2.43",
      "sd": "0.50",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "2.14",
      "sd": "0.52",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "2.02",
      "sd": "0.42",
      "n": "41"
     }
    }
   },
   {
    "measure": "VAS (1, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "1.93",
      "sd": "0.50",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "1.64",
      "sd": "0.48",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "1.54",
      "sd": "0.50",
      "n": "41"
     }
    }
   },
   {
    "measure": "PCIA button presses over 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "6.98",
      "sd": "0.63",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "6.67",
      "sd": "0.65",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "6.46",
      "sd": "0.55",
      "n": "41"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 4 (postoperative 48 h)",
    "values": {
     "Sufentanil group (S1)": {
      "dizziness": "5",
      "hallucination": "3"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "dizziness": "4",
      "hallucination": "5"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "dizziness": "5",
      "hallucination": "5"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-11",
   "end": "2023-12"
  },
  "registration": {
   "number": "ChiCTR2200065198",
   "date": "2022-10-31"
  },
  "note": "Randomized per arm from the sample size paragraph ('we recruited 45 patients per group (total N = 135)'). The Methods also give S1 n = 44, SK1 n = 42, SK2 n = 41 as the allocated groups, but the Results give these as the final analysed groups after losses (S1 1; SK1 3; SK2 4). HAM-D and VAS from Table 2, significance letters dropped; VAS 24 h is day 1 and 48 h day 2. PCIA presses over 48 h from Table 4. Intraoperative remifentanil (day 0) not recorded. Adverse events were collected over the postoperative 48 h. Enrollment dates from Methods."
 },
 {
  "trial": "T092",
  "source": "fulltext",
  "arms": {
   "Esketamine group (group E)": {
    "randomized": "40",
    "analysed": "40"
   },
   "Saline group (group C)": {
    "randomized": "40",
    "analysed": "39"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3",
    "values": {
     "Esketamine group (group E)": {
      "agitation": "1",
      "dizziness": "1"
     },
     "Saline group (group C)": {
      "agitation": "1",
      "dizziness": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-02",
   "end": "2023-06"
  },
  "registration": {
   "number": "ChiCTR2200063302",
   "date": null
  },
  "note": "SAS and SDS only in Figures 2-3 (mean ± SD, no printed values), so no depression entries; the text says postoperative SDS was lower with esketamine (P < .05). The only pain measure is VAS after recovery (0.98 ± 0.73 vs 0.97 ± 0.87, Table 1), day 0, not recorded. Adverse events (Table 3, postoperative): restlessness coded as agitation, vertigo as dizziness. One control patient withdrew. Enrollment dates from Methods."
 },
 {
  "trial": "T101",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "90",
    "analysed": "86"
   },
   "Placebo group": {
    "randomized": "90",
    "analysed": "87"
   }
  },
  "depression": [
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "5",
      "q3": "9",
      "n": "86"
     },
     "Placebo group": {
      "median": "7.0",
      "q1": "4",
      "q3": "10",
      "n": "87"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "86"
     },
     "Placebo group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "87"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "5",
      "q1": "2",
      "q3": "8",
      "n": null
     },
     "Placebo group": {
      "median": "6",
      "q1": "3",
      "q3": "10",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS pain",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at rest)",
    "values": {
     "Esketamine group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": null
     },
     "Placebo group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": null
     }
    }
   },
   {
    "measure": "NRS pain",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at rest)",
    "values": {
     "Esketamine group": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Placebo group": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS score at cough",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "1",
      "q3": "4",
      "n": null
     },
     "Placebo group": {
      "median": "2",
      "q1": "1",
      "q3": "4",
      "n": null
     }
    }
   },
   {
    "measure": "NRS score at cough",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": null
     },
     "Placebo group": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-08-05",
   "end": "2025-06-30"
  },
  "registration": {
   "number": "NCT06530706",
   "date": "2024-07-31"
  },
  "note": "The design's 'NRS pain' carries Table 3's NRS at rest; Table 3's 'NRS score at cough' is recorded under the source's name. PHQ-8 POD3 n is the Table 3 header (POD3 HAMA rows use /86 and /87); POD30 n not given (POD30 HAMA rows use /84 and /85). Pain n not given per day (nausea rows use 84 and 85 esketamine on POD1 and POD2). NRS after extubation (day 0) and at cough on POD30 not recorded. Analysed = primary-analysis numbers. Table 4 reports no psychotomimetic events (hypotension, hypertension, nausea, vomiting only); no serious adverse events."
 }
]